Bioequivalency Study of Zidovudine Under Fasting Conditions
NCT ID: NCT00602550
Last Updated: 2018-01-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
52 participants
INTERVENTIONAL
2003-06-30
2003-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Bioequivalency Study of Zidovudine Under Fed Conditions
NCT00601562
The Safety and Effectiveness of Zidovudine Plus Acyclovir in Patients With Early HIV Infection
NCT00002290
Effect of Steady State TPV/r on Intracellular Concentrations of Zidovudine and Carbovir for Patients With HIV
NCT02229760
A Pharmacokinetic Study of L-697,661 Alone and in Combination With Zidovudine
NCT00000628
The Effectiveness of Three Drug Combinations in HIV-Infected Patients Who Have Taken Zidovudine for More Than 12 Weeks
NCT00001063
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Zidovudine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Participation in clinical trial within 30 days of study initiation.
* Positive blood screen for HIV, Hepatitis B and C.
18 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Roxane Laboratories
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Roxane Laboratories, Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Daniel V Freeland, DO
Role: PRINCIPAL_INVESTIGATOR
CEDRA Clinical Research
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CEDRA Clinical Research
Austin, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ZIDO-03
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.